Institute for Liberal Arts, Environment and Society, Tokyo Institute of Technology, Meguro-ku, Tokyo 152-8550, Japan.
Department of Physical Therapy, Health Sciences University of Hokkaido, Kanazawa, Ishikari-Tobetsu, Hokkaido 061-0293, Japan.
Cells. 2023 Oct 9;12(19):2422. doi: 10.3390/cells12192422.
Sarcopenia is characterized by a gradual slowing of movement due to loss of muscle mass and quality, decreased power and strength, increased risk of injury from falls, and often weakness. This review will focus on recent research trends in nutritional and pharmacological approaches to controlling sarcopenia. Because nutritional studies in humans are fairly limited, this paper includes many results from nutritional studies in mammals. The combination of resistance training with supplements containing amino acids is the gold standard for preventing sarcopenia. Amino acid (HMB) supplementation alone has no significant effect on muscle strength or muscle mass in sarcopenia, but the combination of HMB and exercise (whole body vibration stimulation) is likely to be effective. Tea catechins, soy isoflavones, and ursolic acid are interesting candidates for reducing sarcopenia, but both more detailed basic research on this treatment and clinical studies in humans are needed. Vitamin D supplementation has been shown not to improve sarcopenia in elderly individuals who are not vitamin D-deficient. Myostatin inhibitory drugs have been tried in many neuromuscular diseases, but increases in muscle mass and strength are less likely to be expected. Validation of myostatin inhibitory antibodies in patients with sarcopenia has been positive, but excessive expectations are not warranted.
肌肉减少症的特点是由于肌肉质量和功能下降导致运动逐渐缓慢、力量和体力下降、跌倒受伤风险增加,并且常常伴有虚弱。本次综述将重点关注营养和药理学方法控制肌肉减少症的最新研究趋势。由于人体营养研究相当有限,本文包含了许多来自哺乳动物营养研究的结果。阻力训练与含有氨基酸的补充剂相结合是预防肌肉减少症的黄金标准。单独使用氨基酸(HMB)补充剂对肌肉力量或肌肉质量没有显著影响,但 HMB 和运动(全身振动刺激)的结合可能是有效的。茶儿茶素、大豆异黄酮和熊果酸是减少肌肉减少症的有趣候选物,但需要对这种治疗方法进行更详细的基础研究以及对人类进行临床研究。维生素 D 补充剂并未改善维生素 D 缺乏以外的老年人的肌肉减少症。在许多神经肌肉疾病中已经尝试了肌肉生长抑制素抑制药物,但不太可能期望增加肌肉质量和力量。肌肉生长抑制素抗体在肌肉减少症患者中的验证是积极的,但不应抱有过高的期望。